Angina Pectoris Flashcards

1
Q

Types of Angina and their description

A

Stable Agina
-Heavy pressing substernal discomfort during increased demand for o2
-major cause fixed narrowing of coronary arteries
myocardial ischemia during increased o2 demand

Unstable Angina

  • Discomfort at rest
  • major cause: formation of unstable non-occlusive thrombi lead to transient myocardial ischemia

Variant Angina (angiospastic angina)
-uncommon: discomfort at rest
-major cause: spasm in coronary artery
transient myocardial ischemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Aim of Antianginal Drugs

A

Increased Perfusion of the myocardium
-dilation of coronary vasculature

Decreased metabolic demand
by reducing the cardiac workload

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Why can’t use vasodilator for increasing perfusion of the myocardium

A

Coronary steal phenomenon due to
compensatory response in rearranging blood flow and growing of new blood vessel (collateral)
lead to further decrease in blood supply to the ischemic area which elevates angina symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Name of Nitrates and their usage

A

Nitroglycerin, isosorbide dinitrate

Effective dilators of veins
-decreased amount of blood into the heart (decreased venous return) which decreased cardiac workload and thus myocardial O2 demand

Effective Dilators of Large Arteries
-mildly decreased peripheral vascular resistance (decreased blood pressure) decreased cardiac workload then myocardial O2 demand

Effective dilators of Collateral Coronary Artery
-improve distribution of coronary flow

Decreased coronary artery spasm
effective against variant angina

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Mechanism of Action of Nitrates

A

Nitrate becomes Nitric Oxide NO then lead to the production of cyclic guanosine monophosphate (cGMP)
lead to dephosphorylation of myosin light chain which lead to relaxation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Precautious with use of nitrates

A

Effect of nitrate
-enhanced by phosphodiesterase 5 (PDE5) inhibitor e.g. sildenafil
-additive to that of stimulators of soluble guanylyl cyclase e.g. riociguat
lead to reflex tachycardia due to too much drop in BP
lead to increased in angina symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Pharmacokinetics of Nitrates

A
Rapid metabolism in the liver
-low oral bioavailability which sublingual route is preferred (dose administered via this sublingual route Is limited to avoid excessive effect which leads to brief duration of effect
Rapid Onset
-immediate relief
Short duration of action
Excretion of kidneys
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Unwanted Effects of Nitrates

A

Tolerance (Tachyphylaxis)

  • decreased response to nitrates due to frequently repeated or continuous exposure to nitrates (e.g. with long-acting nitrates isosorbide dinitrates or prolonged infusion or slow-releases forms of short-acting nitrates nitroglycerin
  • avoid high doses
  • administered with a nitrate-free period (8 to 12 hours each day usually at night with low physical activity low o2 metabolic demand )

Dependence

  • withdrawal
  • risk of coronary and digital arteriospasm
  • Not to withdraw nitrates abruptly from a patient after chronic therapy

Adverse Effects

  • headache
  • postural hypotension
  • tachycardia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Characteristics of Different Preparations of Nitrates (Sublingual and Oral)

A

Sublingual Administration

  • fast onset
  • short duration
    • for fast relief and
    • for prevention of anginal pain prior to exercise or stress

Oral administration

  • prophylaxis against anginal episodes in patients with more than occasional angina
  • higher doses and sustained-release preparations (due to low oral bioavailability and rapid metabolism)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Characteristics of Different Preparations of Nitrates (Cutaneous Transmucosal or Buccal, Intravenous )

A

Cutaneous Administration

  • slow onset
  • particularly useful for controlling nocturnal angina

Transmucosal or Buccal Administration
-for short-term prophylaxis of angina
-inserted under the upper lip above the incisors
–gradual release into the circulation for a prolonged period
,
Intravenous Administration
-allow rapid and safely titration of doses
-for relief of coronary vasospasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Name of Calcium Channel Blockers and its effect

A

E.g. nifedipine and amlodipine, diltiazem, verapamil
Decreased force of contraction of the heart
-decreased cardiac workload and hence myocardial o2 demand

Effective vasodilators of Arteries and Arterioles
-decreased peripheral vascular resistance (decreased BP) thus decreased cardiac workload and myocardial o2 demand

Reduced Coronary Artery Spasm
-Effective against variant angina

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Mechanism of Calcium Channel Blockers

A

Inhibit Voltage-Operated Calcium Channels (L-Type)
In the blood vessels
-decreased vasoconstriction and hence peripheral vascular resistance

In the heart
-decreased rate and force of contraction and thus cardiac output

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Adverse Effects of Calcium Channel Blockers

A

Depends on Selectivity on Cardiac or Vascular Smooth muscle

  • Drugs with vascular selectivity e.g. amlodipine, nifedipine
  • -headache, flushing
  • -hypotension which lead to decreased coronary perfusion and reflex tachycardia which both increased angina symptoms
  • Drugs with cardiac selectivity e.g. diltiazem, verapamil
  • -atrioventricular block which lead to heart failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Name and effect of B-Blockers

A

Propanolol, metoprolol

Decreased force and rate of contraction of heart

  • decreased cardiac workload and thus myocardial o2 demand
  • increased duration of diastole and thus increased period of coronary flow and thus increased myocardial perfusion

Increased Coronary Artery Spasm
-avoided in variant angina

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Adverse Effects of

b Blockers

A

Bronchospasm
-contraindicated in patients with asthma or other forms of obstructive airways disease

Hypoglycaemia
-cautious in patients with diabetes

Risk of Arrhythmia and Heart Failure

Risk of Vasospasm
-cautious in patients with severe peripheral vascular diseases or vasospastic disorders

Central Nervous System Disturbance
-cautious in patients with psychiatric disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Nicorandil and its effect

A

Possess Nitrate Like Vasodilator Properties
-which stimulate cGMP production
lead to effects enhanced by phosphodiesterase 5 (PDE 5 inhibitors and stimulators of soluble guanylyl cyclase]

Activate ATP Sensitive Potassium Channels
which increase potassium efflux
lead to vascular smooth muscle hyperpolarization
lead to vasodilatation

Both effect Dilate both arterial and venous vascular beds
[hemodynamic profile lies
in between that of nitrates
and dihydropyridine
calcium channel blockers]
which decrease Coronary artery spasm which is effective against variant angina

17
Q

Adverse Effects of

Nicorandil

A

Headache, Hypotension and Tachycardia
[Same as nitrates
which contraindication of concurrent use of stimulators of soluble guanylyl cyclase or phosphodiesterase 5 (PDE 5 inhibitor]

Increased Risk of Gastrointestinal Ulcerations and Perforations

18
Q

Trimetazidine and its usage

A

Inhibit Long Chain Mitochondrial 3 Ketoacyl Coenzyme A Thiolase 3
KAT) Enzyme [final enzyme in the free fatty acid β oxidation pathway] which
inhibit myocardial fatty acid oxidation thus shift to glucose oxidation for ATP production and increase efficiency of cardiac oxygen utilization

No Major Effect on Heart Rate or Blood Pressure
which can be used in patients with low heart rate or blood pressure

19
Q

Adverse Effects of

Trimetazidine

A

Usually Mild e g gastrointestinal discomfort, muscle cramps, dizziness

Parkinson Syndrome [resolved after drug discontinuation]
which contraindicated in patients with Parkinson diseases or the related movement disorder, or with severely reduced kidney function

20
Q

Ranolazine and its effect

A

Selectively Inhibit the Late Sodium Current in Heart which decrease sodium influx lead to decreased activation of Na ++/Ca 2 exchanger to remove Na
which decrease intracellular calcium concentration which decrease heart contractility which decrease cardiac work

No Major Effect on Heart Rate or Blood Pressure
which can be used in patients with low heart rate or blood pressure

21
Q

Adverse Effects of

Ranolazine

A

Usually Mild e g nausea, dizziness, headache, constipation

22
Q

Precautions with

Ranolazine

A

Metabolized by Liver Cytochrome P 450 CYP) 3A4 Pathway

  • which lead to cautious in patients with hepatic dysfunction
  • which lead to interactions with drugs [e g CYP 3 A 4 inducers or inhibitors]

Modestly Inhibit Potassium Current in Cardiomyocytes

  • which risk of increased duration of action potential
  • therefore cautious in patients with long QT syndrome
23
Q

Ivabradine and its effect

A

Inhibitor of Hyperpolarization Activated Cyclic Nucleotide Gated (HCN) channels
-selectively inhibit I f current in the sinoatrial node (SA node)
-lead to decreased rate of spontaneous depolarization
-which decreases heart rate
thus decreased cardiac work and increased coronary perfusion

24
Q

Adverse Effects of

Ivabradine

A

Bradycardia
-lead to dizziness, weakness or shortness of breath

Phosphenes (Flashes of Light), Blurred Vision
which is due to inhibition of Ih current in the retinal cells

Atrial Fibrillation

25
Q

Contraindications for Ivabradine

A

Resting Heart Rate 60 smaller than Beats Per Minute Blood Pressure lower than 90 50 mmHg

Concurrent Diseases

  • includes acute decompensated heart failure, sinus node dysfunction, pacemaker dependence [i.e heart rate maintained exclusively by the pacemaker]
  • severe hepatic impairment

Concomitant Use of Strong CYP3A4 Inhibitors [e g azole antifungals (itraconzaole macrolide antibiotics (clarithromycin erythromycin)]

Pregnancy, Lactation or Women of Child Bearing Potential Not Using
Appropriate Contraceptive Measures

26
Q

Non-Pharmacological Therapy of Angina

A

Coronary Artery Bypass Grafting (CABG)

Percutaneous Transluminal Coronary Angioplasty (PTCA)

27
Q

Other Pharmacological Therapy of Angina

A

Anti Coagulant Drugs
Anti Platelet Drugs
Both reduces thrombi formation and prevent unstable angina

Lipid lowering drugs
which decreases Atheroma Deposition